Taken together, these results emphasize the protective role of adenosine in hypertensive-diabetic nephropathy through dynamic expression of its receptors, which may be fine-tuned by A2AAR upregulation and A3AR downregulation, thus prompting for a novel therapeutic target for this disease conditions (Patinha et al., 2020). Here, ADORA3 is linked to diabetic kidney disease.